Zomedica Corp. (ZOMDF): R&D Expense
$7.17M
Year ended 2025-12-31
$5.65M
Trailing 12 months to 2026-06-30
+40.6%
3-year compound annual growth
-2.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.17M | -1.4% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $7.27M | +26.5% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $5.74M | +122.8% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $2.58M | +54.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $1.67M | -79.2% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $8.04M | -22.2% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $10.35M | +0.3% | 2021-02-26, From 2019-01-01 |
| 2018-12-31 | $10.32M | +275.0% | 2020-02-26, From 2018-01-01 |
| 2017-12-31 | $2.75M | +81.2% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $1.52M | n/a | 2018-02-28, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
Compare ZOMDF, VSTM, FHTX, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗